Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApTOLL in STEMI (Phase IIa, placebo-controlled)
2023-503751-97-00Phase 2Withdrawn
- Sponsor
- aptaTargets
- Start
- Sep 2023
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing ApTOLL with Placebo (2 arms). Primary endpoints: All-cause mortality within 90 days and Incidence of adverse events within 72 hours. Planned start Sep 2023; status: withdrawn.
02
Drugs
aptoll
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2023-503751-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503751-97-00.